Erythrocyte Complement Receptor 1 and Alzheimer Disease

Not Applicable

Completed

• Conditions: Alzheimer Disease

• Registration Number: NCT01565434
• Lead Sponsor: CHU de Reims

Brief Summary

Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-02
• Status Verified: 2012-03
• Study First Submitted: 2012-03-26
• Study First Submitted QC: 2012-03-27
• Study First Posted: 2012-03-28
• Study Completion: 2015-04
• Last Update Submitted: 2016-06-08
• Last Update Posted: 2016-06-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects

Exclusion Criteria

• diseases modifying CR1 physiology

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

CHU de REIMS; 🇫🇷 Reims, France